How might the results of TREAT-SVDs influence clinical practice? Because of the small sample size, one must be cautious in relation to interpretation of the results. ...according to current European and US guidance for blood pressure management, β blockers are restricted to patients with comorbidities or compelling indications (eg, heart rate control, heart failure, and angina).10 Unless there is a comorbid condition or compelling indication for a β blocker, a reasonable approach for patients with symptomatic cerebral small vessel disease would be to consider administration of a calcium channel blocker or an angiotensin receptor blocker while we await future study results. PBG has served on a data safety and monitoring board for a blood pressure lowering drug administered to heart failure participants for a Novartis sponsored study.